You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華北製藥(600812.SH):重組破傷風疫苗(大腸埃希菌)獲得藥物臨牀試驗批準通知書

格隆匯5月15日丨華北製藥(600812.SH)公佈,下屬控股子公司華北製藥金坦生物技術股份有限公司收到國家藥品監督管理局覈準簽發的重組破傷風疫苗(大腸埃希菌)的《藥物臨牀試驗批準通知書》,破傷風是由破傷風梭狀芽孢桿菌(破傷風桿菌,Clostridiumtetani)引起的感染性細菌性疾病。在厭氧條件下(如被污染的壞死性傷口),破傷風桿菌可產生毒性極強的神經毒素—破傷風痙攣毒素,阻斷中樞神經系統中的抑制性神經遞質,引發肌肉強直和痙攣,亦即破傷風的典型表現。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account